BRCA1/2 in Metastatic Prostate Cancer

Video

An expert considers the role of BRCA1/2 mutations in metastatic prostate cancer.

Matthew Fowler: What is the role of BRCA1/2 in prostate cancer? What percentage of men with prostate cancer harbor a BRCA1 or BRCA2 mutation?

Alicia Morgans, MD, MPH: BRCA2 is the most common. BRCA1 is much less common. When we think about all the DNA-repair defect alterations that we can target with PARP inhibitors, it’s about 11.8% of men with metastatic cancer. About 10% of these might be BRCA2, and a much smaller percentage might be BRCA1. But BRCA2 is the most common in men with prostate cancer. We’ll often see that these men have an aunt with breast cancer or their mother had ovarian cancer, in addition to male family members who have a history of prostate cancer. As we think about these heritable mutations, it’s important to recognize that they can be associated with not just prostate cancer but cancer syndromes outside prostate cancer, including breast and ovarian cancer.

The other important thing to remember is that the guidelines suggest for germline testing in particular that we don’t do only germline testing in men who are younger at the time of diagnosis or who have family members who have a history of these cancers that may be involved in these syndromes. Because what was so fascinating is that the 11.8% of men with metastatic prostate cancer who have these germline heritable mutations didn’t have a higher rate if they had a family member who had a history of one of these cancers. It can be a clue that we may be ready to see one of these alterations in the germline of one of our patients, but it’s not a clear and definite association that would necessarily guide our germline testing.

This transcript has been edited for clarity.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
UPCOMING SERIES
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024
Article

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.

EU’s CHMP Recommends Enzalutamide Approval in Non-Metastatic HSPC

March 25th 2024
Article

The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

BXCL701 Earns FDA FTD in Small Cell Neuroendocrine Prostate Cancer

February 12th 2024
Article

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.

Olaparib Combo Improves Survival Vs Placebo in Metastatic CRPC

January 28th 2024
Article

Findings from the phase 3 PROpel trial suggest that olaparib plus abiraterone acetate may help patients with metastatic castration-resistant prostate cancer live longer, according to Neal Shore, MD, FACS.